Texas Public Radio: New vaccine alleged to have 100% efficacy against original COVID-19 strain

This Texas Public Radio news brief is about the biotechnology company Novavax releasing Phase 3 clinical trial results. UT Health San Antonio collaborated with University Health as part of the international COVID-19 Prevention Network and enrolled 176 Novavax clinical trial participants in San Antonio for the Phase 3 study, which is called PREVENT-19.

Read the story.



Share This Article!
Article Categories: COVID-19 Media Coverage, In the News